<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02847585</url>
  </required_header>
  <id_info>
    <org_study_id>MOST105-2628-B-040-MY2</org_study_id>
    <nct_id>NCT02847585</nct_id>
  </id_info>
  <brief_title>Potential Role of Water-soluble Ubiquinol in Complementary Therapy for Pediatric Dilated Cardiomyopathy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chung Shan Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chung Shan Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pediatric dilated cardiomyopathy (PDCM) is the most common form fond in children.
      Water-soluble coenzyme Q10 (ubiquinol) is better absorbed than lipid-soluble coenzyme Q10
      (ubiquinone) and is directly involved in the antioxidant cycle. Because coenzyme Q10 has
      shown significant health benefits in adult patients with cardiovascular disease, it is worth
      studying water-soluble coenzyme Q10 supplements to evaluate their potential role as
      complementary therapy for PDCM. The purpose of this study is to explore the potential role of
      water-soluble ubiquinol in complementary therapy for pediatric cardiomyopathy. We will
      recruit 25 children with primary PDCM (age 0-20 y) and examine the relationship between
      coenzyme Q10 level and cardiac function (left ventricular fractional shortening and ejection
      fraction, and B-type natriuretic peptide), oxidative stress (malondialdehyde), antioxidant
      enzymes activity (catalase, glutathione peroxide, and superoxide dismutase), and inflammation
      (high sensitivity C-reactive protein and interleukin-6) in PMC after 6 months water-soluble
      ubiquinol supplementation (10 mg/kg BW/d, by oral drops). In addition, we will assess the
      quality of life of PDCM patients by questionnaire. Through this study, we expect to
      demonstrate that water-soluble coenzyme Q10 will be a complementary therapy for PDCM, and
      will improve cardiac function, increase antioxidant capacity, slow deterioration of cardiac
      function and reduce inflammation, and further reduce the rate of heart transplantation and
      increase quality of life in PDCM.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular ejection fraction</measure>
    <time_frame>6 months</time_frame>
    <description>Left ventricular ejection fraction (%) will be measured by cardiac echo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of plasma coenzyme Q10</measure>
    <time_frame>6 months</time_frame>
    <description>Plasma coenzyme Q10 (micromol/L) will be measured by high performance liquid chromatography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-type natriuretic peptide (BNP)</measure>
    <time_frame>6 months</time_frame>
    <description>BNP (pg/mL) will be measured by fluorescence immunoassay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>malondialdehyde (MDA)</measure>
    <time_frame>6 months</time_frame>
    <description>MDA (micromol/L) will be measured by thiobarbituric acid reacting substance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>catalase (CAT)</measure>
    <time_frame>6 months</time_frame>
    <description>red blood cells level of CAT in unit/mg protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glutathione peroxide (GPx)</measure>
    <time_frame>6 months</time_frame>
    <description>red blood cells level of GPx in unit/mg protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>superoxide dismutase (SOD)</measure>
    <time_frame>6 months</time_frame>
    <description>red blood cells level of SOD in unit/mg protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>high sensitivity C-reactive protein (hs-CRP)</measure>
    <time_frame>6 months</time_frame>
    <description>hs-CRP (mg/dL) will be measured by Immunoturbidimetry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>high sensitivity interleukin-6 (IL-6)</measure>
    <time_frame>6 months</time_frame>
    <description>IL-6 (pg/dL) will be measured by immunosorbent assay.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Pediatric Dilated Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>water-soluble ubiquinol</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Water-soluble Ubiquinol</intervention_name>
    <description>10 mg/kg BW/d, by oral drops</description>
    <arm_group_label>Open label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric dilated cardiomyopathy defined as left ventricular ejection fraction â‰¤ 40 %
             by cardiac echo examination.

        Exclusion Criteria:

          -  Hypertension

          -  Arrhythmia

          -  Congenital heart defects

          -  Acute myocarditis

          -  Pregnant and lactating teens

          -  Antioxidant vitamins users
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ping-Ting Lin, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>School of Nutrition, Chung Shan Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ping-Ting Lin, Ph.D.</last_name>
    <phone>+886-4-24730022</phone>
    <phone_ext>12187</phone_ext>
    <email>apt810@csmu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chung Shan Medical University</name>
      <address>
        <city>Taichung</city>
        <zip>40201</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping-Ting Lin, Ph.D.</last_name>
      <phone>+886-2473-0022</phone>
      <phone_ext>12187</phone_ext>
      <email>apt810@csmu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2016</study_first_submitted>
  <study_first_submitted_qc>July 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2016</study_first_posted>
  <last_update_submitted>February 24, 2017</last_update_submitted>
  <last_update_submitted_qc>February 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chung Shan Medical University</investigator_affiliation>
    <investigator_full_name>Yeh</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>water-soluble ubiquinol supplementation</keyword>
  <keyword>pediatric cardiomyopathy</keyword>
  <keyword>antioxidant</keyword>
  <keyword>inflammation</keyword>
  <keyword>complementary therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

